Arovella expands Scientific Advisory Board with the appointment of Professor Gianpietro Dotti
Highlights:
Arovella is honoured to appoint CAR-iNKT cell pioneer Professor Gianpietro Dotti to its Scientific Advisory Board;
Professor Dotti has spent more than 20 years using his medical and scientific background to use gene-modified immune cells to treat blood cancers and solid tumours;
Professor Dotti has played an integral role developing CAR-iNKT cell therapeutics in solid tumours in paediatric patients.
MELBOURNE, AUSTRALIA 03 April 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is delighted to welcome Professor Gianpietro Dotti to its Scientific Advisory Board.
Arovella is one of only several companies globally developing CAR-iNKT cells for cancer treatment. Professor Gianpietro Dotti's appointment strengthens Arovella’s expertise in using CAR-iNKT cells to treat blood cancers and solid tumours. Professor Dotti is a pioneer and one of the first individuals to create CAR-iNKT cell strategies for cancer treatment. He has been involved in the development of two products using CAR-iNKT cells that have been used in blood cancer patients and paediatric patients with neuroblastoma.
Professor Dotti has spent more than twenty years using his medical and scientific training to create engineered immune cells for cancer treatment. His research has led to more than 200 peer-reviewed articles, and he has consistently received the Highly Cited Researchers (Top 1%) award from Web of Science, Clarivate Analytics in 2020, 2021, 2022, and 2023.
Professor Dotti received his medical degree from the University of Milan, Italy and completed his clinical training and Board certification in haematology from the University of Parma. He completed his post-doctoral fellowship at the Center for Cell and Gene Therapy at the Baylor College of Medicine in Houston, Texas.
Professor Dotti is currently a Professor of Microbiology and Immunology, and the Director of the Cellular Immunotherapy Program at Lineberger Comprehensive Cancer Center at the University of North Carolina.
Arovella’s CEO and MD, Dr Michael Baker, commented: “We are honoured and grateful to have someone of Giampietro’s calibre join our Scientific Advisory Board. He is a remarkable individual, and his scientific involvement in developing and manufacturing CAR-iNKT cells will be a valuable addition to Arovella and our ongoing programs, which are now funded to take into clinical trials. We warmly welcome Gianpietro to Arovella’s Scientific Advisory Board.”